FINWIRES · TerminalLIVE
FINWIRES

HCAヘルスケア、第1四半期の業績が予想を上回り、呼吸器疾患による入院患者数は減少

-- HCAヘルスケア（HCA）の第1四半期決算は市場予想を上回ったものの、同社は呼吸器疾患の減少により、例年見られる季節的な入院患者数の増加は見られなかったと発表した。 同社は金曜日、3月31日締めの第1四半期の調整後1株当たり利益が7.15ドルとなり、前年同期の6.45ドルから増加し、ファクトセットが調査した市場予想の7.12ドルを上回ったと発表した。売上高は4.3%増の191億1000万ドルとなり、市場予想の190億9000万ドルを上回った。 HCAヘルスケアは、主に呼吸器疾患の減少により、第1四半期に例年見られる季節的な患者数の増加が見られなかったと述べた。呼吸器疾患関連の入院患者数は前年同期比で42%減少し、呼吸器疾患関連の救急外来受診者数も32%減少した。1月の冬の嵐も、一部の地域で四半期の患者数に影響を与えたと同社は述べている。 同社によると、不利な販売量減少要因は、当初の通期見通しには反映されていなかったメディケイド補足プログラムの導入によってほぼ相殺された。 HCAヘルスケアの株価は金曜日の取引で7.4%下落し、年初来の下落率は7.6%に拡大した。 「年初はHCAヘルスケアにとって変化の激しい環境だった」と、サム・ヘイゼン最高経営責任者（CEO）は声明で述べた。 同社によると、既存施設の入院患者数は0.9%増加し、救急外来受診者数も0.3%増加した。既存施設の入院手術件数は0.3%減少し、外来手術件数は1.7%減少した。 同社は引き続き、2026年の純利益を1株当たり29.10ドルから31.50ドル、売上高を765億ドルから800億ドルと予測している。市場は同年の1株当たり利益を30.39ドル、売上高を786億ドルと予想している。

Price: $448.41, Change: $-25.62, Percent Change: -5.40%

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.

$HIG
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.

$BKR
Research

Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.

$WAB